Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001171843-21-002455
Filing Date
2021-04-13
Accepted
2021-04-13 16:15:57
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A defa14a_040121.htm DEFA14A 12578
2 GRAPHIC bcrx_01.jpg GRAPHIC 88333
3 GRAPHIC bcrx_02.jpg GRAPHIC 73165
  Complete submission text file 0001171843-21-002455.txt   236296
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-23186 | Film No.: 21823259
SIC: 2836 Biological Products, (No Diagnostic Substances)